Arrowhead Pharmaceuticals, Inc. (ARWR): Price and Financial Metrics
ARWR Price/Volume Stats
Current price | $28.68 | 52-week high | $42.48 |
Prev. close | $28.70 | 52-week low | $20.67 |
Day low | $28.04 | Volume | 214,252 |
Day high | $29.08 | Avg. volume | 1,629,201 |
50-day MA | $31.17 | Dividend yield | N/A |
200-day MA | $30.09 | Market Cap | 3.55B |
ARWR Stock Price Chart Interactive Chart >
ARWR POWR Grades
- Value is the dimension where ARWR ranks best; there it ranks ahead of 62.37% of US stocks.
- ARWR's strongest trending metric is Growth; it's been moving down over the last 26 weeks.
- ARWR's current lowest rank is in the Growth metric (where it is better than 7.92% of US stocks).
ARWR Stock Summary
- Of note is the ratio of ARROWHEAD PHARMACEUTICALS INC's sales and general administrative expense to its total operating expenses; only 7.8% of US stocks have a lower such ratio.
- With a price/sales ratio of 14.27, ARROWHEAD PHARMACEUTICALS INC has a higher such ratio than 92.37% of stocks in our set.
- With a year-over-year growth in debt of 41.18%, ARROWHEAD PHARMACEUTICALS INC's debt growth rate surpasses 85.23% of about US stocks.
- Stocks that are quantitatively similar to ARWR, based on their financial statements, market capitalization, and price volatility, are NTLA, IGMS, RNA, VIR, and DNLI.
- Visit ARWR's SEC page to see the company's official filings. To visit the company's web site, go to arrowheadpharma.com.
ARWR Valuation Summary
- ARWR's price/sales ratio is 13.7; this is 522.73% higher than that of the median Healthcare stock.
- Over the past 237 months, ARWR's EV/EBIT ratio has gone NA NA.
Below are key valuation metrics over time for ARWR.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
ARWR | 2023-12-29 | 13.7 | 12.1 | -16.0 | -17.9 |
ARWR | 2023-12-28 | 13.8 | 12.3 | -16.2 | -18.1 |
ARWR | 2023-12-27 | 13.8 | 12.3 | -16.2 | -18.1 |
ARWR | 2023-12-26 | 13.8 | 12.2 | -16.2 | -18.0 |
ARWR | 2023-12-22 | 13.5 | 12.0 | -15.9 | -17.7 |
ARWR | 2023-12-21 | 12.8 | 11.4 | -15.1 | -16.8 |
ARWR Growth Metrics
- Its 2 year price growth rate is now at -2.39%.
- Its year over year price growth rate is now at -48.42%.
- Its 3 year revenue growth rate is now at 177.9%.
The table below shows ARWR's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-12-31 | 278.338 | -150.3 | -154.516 |
2022-09-30 | 243.231 | -136.131 | -176.063 |
2022-06-30 | 249.939 | -91.581 | -153.926 |
2022-03-31 | 263.418 | -52.344 | -111.804 |
2021-12-31 | 144.424 | 148.799 | -182.988 |
2021-09-30 | 138.287 | 171.224 | -140.848 |
ARWR's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ARWR has a Quality Grade of C, ranking ahead of 55.82% of graded US stocks.
- ARWR's asset turnover comes in at 0.171 -- ranking 211th of 682 Pharmaceutical Products stocks.
- COLL, CRBP, and VBIV are the stocks whose asset turnover ratios are most correlated with ARWR.
The table below shows ARWR's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.171 | 1 | -0.460 |
2021-03-31 | 0.153 | 1 | -0.385 |
2020-12-31 | 0.149 | 1 | -0.363 |
2020-09-30 | 0.158 | 1 | -0.397 |
2020-06-30 | 0.241 | 1 | -0.218 |
2020-03-31 | 0.303 | 1 | 0.013 |
ARWR Price Target
For more insight on analysts targets of ARWR, see our ARWR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $87.92 | Average Broker Recommendation | 1.59 (Moderate Buy) |
Arrowhead Pharmaceuticals, Inc. (ARWR) Company Bio
Arrowhead Pharmaceuticals is a biopharmaceutical company developing targeted RNAi therapeutics. The company was founded in 1989 and is based in Pasadena, California.
Latest ARWR News From Around the Web
Below are the latest news stories about ARROWHEAD PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ARWR as an investment opportunity.
Arrowhead Pharmaceuticals Inc CEO Christopher Anzalone Sells 12,000 SharesArrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CEO Christopher Anzalone sold 12,000 shares of the company's stock on December 20, 2023, according to a recent SEC filing. |
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney DiseasePASADENA, Calif., December 21, 2023--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for complement mediated renal disease, such as immunoglobulin A nephropathy (IgAN), which is the most common glomerular disease worldwide and carries a high lifetime risk of progression to end-st |
Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferencePASADENA, Calif., December 20, 2023--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, at 8:15 a.m. PT. |
ARWR: Updates on Plozasiran and Zodasiran at AHA 2023…By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Updated Clinical Data for Cardiometabolic Candidates Presented at AHA 2023 On November 13, 2023, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) announced new clinical data for the Phase 2 SHASTA-2 and MUIR studies of plozasiran (ARO-APOC3) and the ARCHES-2 study of zodasiran (ARO-ANG3) were presented at the American |
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2023 Earnings Call TranscriptArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2023 Earnings Call Transcript November 29, 2023 Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today’s recorded presentation, all participants will be in a listen-only. After the presentation, there will be an opportunity to ask questions. I will now hand the conference call over to Vince […] |
ARWR Price Returns
1-mo | -7.97% |
3-mo | -6.27% |
6-mo | 6.74% |
1-year | 15.93% |
3-year | -53.25% |
5-year | 56.29% |
YTD | -6.27% |
2023 | -24.56% |
2022 | -38.82% |
2021 | -13.59% |
2020 | 20.97% |
2019 | 410.71% |
Continue Researching ARWR
Here are a few links from around the web to help you further your research on Arrowhead Pharmaceuticals Inc's stock as an investment opportunity:Arrowhead Pharmaceuticals Inc (ARWR) Stock Price | Nasdaq
Arrowhead Pharmaceuticals Inc (ARWR) Stock Quote, History and News - Yahoo Finance
Arrowhead Pharmaceuticals Inc (ARWR) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...